Abstract
NAA10 encodes for the enzyme NAA10, which is the catalytic subunit in the N-terminal acetyltransferase A (NatA) complex. N-alpha-acetylation is one of the most common co-translational protein modifications in humans and is essential for normal cell function. The auxiliary and regulatory subunits of the NatA complex are NAA15 and Huntington-interacting protein (HYPK), respectively. Through a genotype-first approach with primarily exome sequencing, one clinician identified and interviewed the parents of 56 individuals with NAA10 variants and 19 individuals with NAA15 variants. Clinical features of affected individuals include variable levels of intellectual disability, delayed speech and motor milestones and autism spectrum disorder, which are usually more severe in individuals with NAA10 variants compared to those with NAA15 variants. Additionally, some individuals present with mild craniofacial dysmorphology, congenital cardiac anomalies and seizures. The majority of individuals with NAA10 variants present with visual abnormalities, which often include astigmatism, myopia, strabismus, amblyopia, and/or cortical visual impairment. Further, there are a subset of individuals who have exotropia/esotropia, microphthalmia, blindness, and/or have abnormalities to the optic disc or nerve. In individuals with NAA15 variants, visual abnormalities were present in a small subset with strabismus, amblyopia, astigmatism, and other visual impairment, with many individuals affected by this syndrome wearing eyeglasses. We discovered a female (Individual 23) with the common p.Arg83Cys variant, yet she is the only female published to date who was born with microphthalmia, along with stigmatism in her left eye, myopia and possible cortical visual impairment. We report another male with microphthalmia with a frameshift p.Thr152Argfs*6 variant in NAA10. Vineland-3 functional assessment demonstrates that the overall level of functioning for the probands with NAA15 variants was significantly higher than the probands with NAA10 variants. When the results for NAA10 are separated by sex, inheritance pattern, and variant type, it is clear that the frameshift variants located toward the C-terminal end of NAA10 have much less impact on overall functioning. The females with the p.Arg83Cys missense in NAA10 have a similar level of impairment to the females with other missense changes in NAA10. The overall data are consistent with a phenotypic spectrum for these alleles involving multiple organ systems, including visual development, and as such we suggest that the condition involving NAA10 should be interchangeably referred to as Ogden syndrome and/or NAA10-related neurodevelopmental syndrome, and the condition involving NAA15 should be referred to as NAA15-related neurodevelopmental syndrome.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work is supported by New York State Office for People with Developmental Disabilities (OPWDD) and NIH NIGMS R35-GM-133408. NIH grants R01 GM060293 and R35 GM118090 awarded to R.M. and T32 GM071339 grant awarded to L.G. also supported this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Both oral and written patient consent were obtained for research and publication, with approval of protocol #7659 for the Jervis Clinic by the New York State Psychiatric Institute - Columbia University Department of Psychiatry Institutional Review Board. Written family consent was given for publication of any photography of the children.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors. The sequencing data were generated as part of clinical testing, so the underlying raw data are not consented for deposition to a public database.
https://humandiseasegenes.nl/naa10/
